Redeye is positive about Kardium’s FDA approval for the Globe system, which allows the commercial phase to begin. As our previous sales projections were risk-adjusted, we now make some changes to our forecasts. These revisions result in an updated fair value range for Corline.

Läs mer på Redeye

Ämnen i artikeln


Corline Biomedical

Senast

14,35

1 dag %

−0,35%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån